Liu Vincent, White Dorothy A, Zakowski Maureen F, Travis William, Kris Mark G, Ginsberg Michelle S, Miller Vincent A, Azzoli Christopher G
Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Chest. 2007 Sep;132(3):1042-4. doi: 10.1378/chest.07-0050.
Interstitial lung disease (ILD) related to therapy with the drug gefitinib has been well reported. The adverse pulmonary effects of erlotinib are less well known. We report a case of fatal pulmonary toxicity in a patient with advanced non-small cell lung cancer who received erlotinib. He had been found to have pathologic findings of usual interstitial pneumonia (UIP) on the resected lung cancer specimen prior to receiving erlotinib. This case and other published evidence should alert physicians to the possibility of fatal erlotinib-induced ILD. Similar to reports in patients receiving gefitinib, those with pathologic findings of UIP on resected lung specimens or known pulmonary fibrosis may be at particular risk for erlotinib pulmonary toxicity.
与吉非替尼治疗相关的间质性肺病（ILD）已有大量报道。厄洛替尼的肺部不良反应则鲜为人知。我们报告一例接受厄洛替尼治疗的晚期非小细胞肺癌患者发生致命性肺毒性的病例。在接受厄洛替尼治疗之前，他在切除的肺癌标本上被发现有普通型间质性肺炎（UIP）的病理表现。该病例及其他已发表的证据应提醒医生注意厄洛替尼诱发致命性ILD的可能性。与接受吉非替尼治疗的患者报告相似，在切除的肺标本上有UIP病理表现或已知有肺纤维化的患者可能尤其有发生厄洛替尼肺毒性的风险。
